SABS Earnings

Quarterly EPS
$-1.12
Q3 2024
$-1.23
Q4 2024
$-0.56
Q1 2025
$-1.09
Q2 2025
$0.50
Q3 2025
$-0.06
Q4 2025
$-0.35
Q1 2026
$-0.28
Q2 2026
Latest RevenueN/A
Latest Net Income-22491000
EPS & Revenue Trend
PeriodEPSRevenueNet IncomeRev YoYEPS YoY
Q2 2026-$0.280-22491000+74.3%
Q1 2026-$0.350-18868885+37.5%
Q4 2025-$0.060-16860743-100.0%+95.1%
Q3 2025$0.50045.4M+144.6%
Q2 2025-$1.090-10114000-100.0%-38.0%
Q1 2025-$0.560-5196773-100.0%-3.7%
Q4 2024-$1.23114.7K-11394699-62.4%+63.6%
Q3 2024-$1.120-10349410-100.0%-15.5%
Q2 2024-$0.79263.1K-7335455
Q1 2024-$0.54944.6K-5025745
Q4 2023-$3.38305.0K-22856763
Q3 2023-$0.971.3M-5102317
SAB Biotherapeutics (SABS) — Earnings